Saturday, March 17, 2012

AstraZeneca Sues the FDA to extend Seroquel patent & profits - The outrageous hypocrisy of it all


AstraZeneca  Sues the FDA to extend Seroquel patent & profits - The outrageous hypocrisy of it all

Yes, it's beyond ludicrous I know....but those very same greed mongering corporate thugs @ AstraZeneca who have stolen literally mountains of money by their blatant acts of illegal marketing, political pandering & deceit, and by hiding the dangerous & deadly side effects of the drug Seroquel while making it a multi-billion dollar a year block buster; are now suing the FDA because the soon to be released generic version of Seroquel doesn't have the exact same label warning incert as the AstraZeneca patented version. 

Now, very few rational people are going to argue that full, safe, and complete product labeling isn't a good thing. But let's get real here....AstraZeneca has never been concerned about safety or patient health when it comes to Seroquel...they sure as hell didn't want consumers (or anyone else for that matter) knowing all the dirty secrets and dangerous details of this drug when marketing Seroquel into a mega billion dollar per year profit maker. Now they want to hold on to their deadly cash cow patent even longer...please give us all a break...this is yet another case of the special & privileged corporate elite abusing the legal system, the citizens of America, & others from around the world purely for greed's sake.

-------------------------------------------------------------------------------------------

AZ's Seroquel Battle with FDA: A Mark of Desperation?

By Ana Nicholls, Healthcare Analyst at the Economist Intelligence Unit.

Is it a mark of desperation? UK-based pharma company AstraZeneca has resorted to suing the US Food and Drug Administration in a bid to stop it from approving generic competition to Seroquel, the company’s blockbuster anti-depressant, before December 2012. The core patent for Seroquel IR expired in September last year, and its paediatric patent runs out this month, although Seroquel XR (the later version) still has protection till 2017.


The FDA has yet to approve a generic version, and AstraZeneca is arguing that it should not do so. The company claims that important decisions have still not been made over warning labels on the generic versions of Seroquel IR, which need to mimic those on the original, while it still has data exclusivity rights stemming from the clinical trials it has conducted.


AstraZeneca tried a Citizens’ Petition against the FDA earlier this month, with no joy, so it is now trying a lawsuit. The case is a long shot, but the costs will certainly be far lower than the losses the company will incur when Seroquel’s patent expires. The drug generated sales of US$4.3bn worldwide last year, of which US$3.3bn was in the US. Moreover, if AstraZeneca wins, then it (and other companies) may also have developed another way of extending protection for many of the drugs that are coming off-patent.


If so, that would be very welcome news in this, the steepest year of the patent cliff. This year, around US$27bn-worth of blockbuster sales will be exposed to generic competition in the US, according to Fitch Ratings. AZ, along with Pfizer and Forest Laboratories of the US, is one of the companies hardest hit. AZ calculates that it lost almost US$2bn in revenue during 2011 as a result of generic competition. Other companies have tried different tactics to protect their patents – Pfizer, for example, struck exclusivity deals with pharmacy benefits managers to protect sales of Lipitor after its US patent expired late last year.

Yet the mood in the US is firmly against pharma companies who are seen as blocking competition, making the likelihood of AZ winning its case appear remote. Though attempts to legislate have foundered, the current US government has campaigned against what it dubs “pay-for-delay” tactics, which mainly involve deals between pharma companies and their potential generic competitors. The chairman of the Federal Trade Council Jon Leibowitz claimed last year that such arrangements cost consumer US$3.5bn a year in higher drug prices.

---------------------------------------------

Once again in this article above, Seroquel is being referred to as an antidepressant drug - so let's make it absolutely clear, and correct once again this often used blatant mistake reported by the main stream media & others.

Seroquel is not an antidepressant drug...it is a powerful neuroleptic drug (anti-psychotic).

neuroleptic drug - tranquilizer used to treat psychotic conditions when a calming effect is desired

Busted in Louisiana: For attempting to sell AstraZeneca's Seroquel,and possession of Seroquel and marijuana

Prescription drug street sales attempt of antipsychotic Seroquel

NEWS: Monroe, Louisiana
Monroe police arrested a man Monday evening accused of drug possession near a child.
Glenn Armstrong, 19, of 1702 Railroad Ave., Monroe, was booked into Ouachita Correctional Center on charges of possession of Seroquel, possession of marijuana, possession of controlled and dangerous substances in the presence of juveniles, stop sign violation, no driver's license and no insurance.
An arrest affidavit stated an officer was traveling westbound on Texas Avenue when he saw the driver of a Mazda vehicle run a red traffic light at the intersection with South Second Street. Police said the driver, later identified as Armstrong, stopped in the 500 block of South First Street.During the traffic stop, police said Armstrong could not show them a proper driver's license or proof of insurance. Police said Armstrong appeared to be nervous.
The report stated police saw two 16-year-old juveniles in Armstrong's vehicle. A search of the vehicle revealed a bottle of suspected Seroquel pills and a small bag of suspected marijuana. The unnamed juveniles told police Armstrong had been trying to sell the suspected pills before he was stopped.
Bond was $16,050.


MPD accuses suspect of having drugs near child

----------------------------------------------------------------------------------

And also in the news....an article that can be placed in the category of doing much too little, far too late....

State puts lid on overprescribing doctors


Pennsylvania has investigated and removed some doctors who were among the top prescribers of painkillers and mental health drugs for Medicaid patients, officials said in a letter made public on Friday.

Five doctors were disqualified from participating in the program; four had their licenses suspended; two were referred to prosecutors for review; and one is under investigation, the state Department of Public Welfare told U.S. Senate investigators.

The state reported its actions in a Feb. 27 letter to Sen. Charles Grassley, R-Iowa, who has been investigating abuses nationwide of medicines such as the anti-depressant Xanax. Pennsylvania initially provided information about the top 10 prescribers of eight antipsychotic, painkiller or anti-anxiety drugs to Grassley in 2010.

"We are seeing that certain states, including Pennsylvania, are reporting that they or the state medical board has taken action against medical providers, and that's good news," said Jill Gerber, Grassley's spokeswoman.

The state welfare department said it sent intervention letters to 51 other doctors, showing their patients' drug histories. The state said its program encourages doctors to discontinue unnecessary prescriptions, reduce drug quantities or switch to other treatments.
State officials declined to identify any doctors.

"Our administration is dedicated to rooting out all waste, abuse and fraud in our programs and services," spokeswoman Donna Kirker Morgan said in a statement.

"Although the senator's questions are an interesting snapshot of antipsychotic drug utilization in the Medicaid system, the questions do not delve into important facts and backgrounds about patients and their current needs for such drugs and the circumstances for such prescriptions."

Top prescribers continue to dispense many of the drugs at a high cost for taxpayers, the state's response shows. Along with its letter, public welfare reported the top 10 prescribers for eight drugs, showing the number of prescriptions each doctor wrote and the dollar value of them.
One doctor last year gave out 6,950 prescriptions for Xanax — or more than 19 every day — at a cost of nearly $70,500. The year before, another doctor wrote 1,864 prescriptions for Seroquel, an antidepression and schizophrenia drug that can cost up to $12 per tablet. The Seroquel prescriptions cost taxpayers more than $1 million.

The state attorney general's office could not immediately provide details about whether any of the public welfare referrals resulted in prosecution. "We aggressively pursue provider fraud, which diverts limited taxpayer resources from Medicaid recipients with legitimate needs," spokesman Nils Hagen-Frederiksen said.

The state's response to Grassley was made public yesterday when the agency responded to a Right-to-Know Request filed by Ken Kramer, an investigator for Citizens Commission on Human Rights International, a group that investigates and exposes psychiatric abuse.

"It's very good to see Pennsylvania taking action," Kramer, 55, of Clearwater, Fla., said in an email to the Tribune-Review. "There is no debate on this: Patients are overdrugged, Medicaid is overbilled and taxpayers are overburdened -- all caused by the bogus prescribing of psychiatrists."

--------------------------------------------------------------------

So everyone is absolutely clear and to correct a blatant mistake often reported by media. Seroquel is not an anti-depressant drug...it is a powerful neuroleptic drug (anti-psychotic). 
neuroleptic drug - tranquilizer used to treat psychotic conditions when a calming effect is desired

Thursday, March 15, 2012

AstraZeneca Seroquel Litigation Update - The Miller Firm LLC, Ennis & Ennis, P.A., and Saiontz & Kirk, P.A. "You Had A Lawyer" - Are Law Firms Using Legal Sleight of Hand to Force Through a Rejected Settlement Offer?

AstraZeneca Seroquel Litigation Update - The Miller Firm LLC, Ennis & Ennis, P.A., and Saiontz & Kirk, P.A. "You Had A Lawyer" - Are Law Firms Using Legal Sleight of Hand to Force Through a Rejected Settlement Offer?

Where we left off in the last Post HERE , The Miller Firm LLC was reporting they had magically reached 78% acceptance figure for the Seroquel settlement offer; even though for many months there has been a 40% rejection of the same settlement offer. This week on The Miller Firm Seroquel Update Recording (*800* 882 -2525) states that they have now reached an 85% approval; while going further to boast & state that they will meet their goal this week ( 93% approval is needed for the settlement to go forward) .

WOW!! How does something like this happen? Shall we start wondering how one goes (in a couple of weeks) from a settlement that was dead and buried to a miraculous acceptance of 93%?

1. We know these firms have been marketing the heck out of this lousy settlement for almost a year now..

2. We also know The Miller Firm had/has made in quite clear to anyone appealing the process or who has not signed onto this settlement would be dropped from representation (evidenced by The Miller Firms numerous statements that there would be absolutely no re-negotiations, that client appeals would & have been ignored, & there would zero trials going forward).

3. We also know the stated settlement deadlines have come & gone....then out of thin air are being extended only to suite the law firms whimsical insistence that this settlement be accepted for their own selfish gain...(not acting in the clients best interest)

OK, we know that the above statements has been the sleazy case & hard to stomach reality for some time now....so what else has magically changed in the past couple of weeks?

4. How about the dumping of clients! it sure appears that The Miller Firm has conspired against & jettisoned clients that did not accept the settlement, & are holding back that information/notification until they get the settlement money in their grubby and greedy legal mitts; and are recalculating (or are now in the process of recalculating) the new numbers to meet the 93% acceptance threshold criteria for AstraZeneca to release settlement funds. It's not like it's any hidden secret at this juncture that The Miller Firm & their Sleazy "gather & sell clients" co-counsel are in this for the money & very little else.....

Now if that is what has actually happened; then not only is it not kosher or ethical;  It also flies in the face of any reasonable or rational comprehension of the original settlement offer which was supposedly sent out to all the 623 clients The Miller Firm were supposedly representing. 

Radical changes in events and the status of tort settlements don't just change like this overnight....There must be explanations, extenuating factors or justifiable reasons behind such changes....I believe clients have a right to know....after all....who is The Miller Firm & their co-counsel legally and ethically bound to represent in their best interest....the clients or just themselves?

Of course The Miller Firm as usual is being very secretive, tight lipped, and closed mouth about what they are doing...They will only make references or comments related to pushing this offer through at all cost & nothing else.

 In fact, anyone questioning the process or this settlement approval push is ostracized from not only the entire process, but from all pertinent information & inquiry (including receiving mailings and letters that were supposedly sent out to all represented clients!!).

Considering The Miller Firms track record and history of supplying misleading/misinformation/bullshit (lies) throughout this whole ordeal; I & others are calling for the court and federal authorities to investigation the practices and actions that have been used and employed by The Miller Firm and related co-counsel throughout this litigation. Something smells completely rotten here; injured clients & the public have a right to know what's really going on!

Monday, March 12, 2012

AstraZeneca Seroquel Litigation Update - The Miller Firm LLC, Ennis and Ennis, P.A., & Saiontz & Kirk, P.A. "You Had a Lawyer" - Legalized Snake Oil Salesman - The selling of a bad settlement for profit


 AstraZeneca Seroquel Litigation Update - The Miller Firm LLC, Ennis and Ennis, P.A., & Saiontz & Kirk, P.A. "You Had a Lawyer" - Legalized Snake Oil Salesman - The selling of a bad settlement for profit 


It’s appears The Miller Firm (including client gathering and case selling non-participant co-counsel Saiontz & Kirk, P.A , Ennis&Ennis, P.A. ) are in a desperate “sell the failed settlement” at all cost mode presently. Just three weeks ago The Miller Firm had stated in their update phone recording that they only had somewhere around 60% of the 93% settlement acceptance needed for the Seroquel settlement to fly. This past week after a concerted “Sell the Settlement” campaign they are now claiming a 78% acceptance figure; while also claiming that they have mailed out a “letter” to all their Seroquel Clients.

The Miller Firm seems to say a lot of things…yet how much of it is truth, and how much of it is just meaningless bravado & blatant lies? 

Let's look at this example from The Miller Firm web site:
I & others can attest that this statement & claim is complete bullshit, & one utter laughable falsehood.

I happen to personally stay in contact with some of The Miller Firm clients. One of sources stated The Miller Firm had told them three weeks ago that they were being dropped as a client for not accepting the settlement offer & would receive a letter stating that fact within seven days; That letter has never arrived! This same client also has not received this latest “sell the settlement” propaganda letter The Miller Firm has claimed to have sent out to “all” of their clients.

It is truly a nasty & underhanded business for ambulance chaser firms like “Miller” who are attempting to sell a horrible & unfair settlement offer for AstraZeneca & themselves, while throwing actual injured parties under the bus.

 In fact, it’s actually quite difficult to differentiate who is worse or more evil in this litigation: AstraZeneca whose product Seroquel has purposely harmed & killed so many to make Money, or the plaintiff law firms that are using their Seroquel clients simply as cash cows to collect large windfall paydays for themselves.

There’s only one thing we know for sure & as absolute truth: Seroquel injured parties are not receiving proper representation or anything that can be construed as being within the realm of actual justice. This whole litigation amounts to nothing more than shady backrooms and a very secretive member’s only club of greedy & self serving individuals/law firms that are shaking down those forever injured  Seroquel clients for their own personal profit & gain.

The numbers don't lie:

So how does The Miller Firm offer stack up against other settlement offers in this litigation?: SAME COURT, SAME DRUG, SAME INJURIES -

Weitz & Luxenberg P.C.
92.5 million dollar distribution pot
2351 clients
(before deductions) average claim = 39 thousand & change (an embarrassing pittance)

The Miller Firm LLC
6.9 million dollar distribution pot
623 clients
(before deductions) average claim = 11 thousand & change (a complete insult)

(Please note this settlement is not & has never been about injuries suffered by claimants, or holding AstraZeneca accountable for their despicable actions : it is only about the cost of continuing to litigate claims. The Plaintiff law firms have created out of thin air a false & misleading perception that this settlement offer is about receiving compensation for injuries incurred!  IT IS NOT! That is a disingenuous ploy & misrepresentation of reality being used to sell this settlement and for nothing else)


Now let us look at the numbers in The Miller Firm settlement offer that they are so desperately selling their clients at present: (ask yourself who is winning and who is losing here?)

The Miller Firm Settlement offer for an estimated 623 Seroquel Clients: 

Total Settlement Offer is roughly 7.4 million dollars (including hold back funds). 


The Miller Firm & their Co-counsel are taking 40% plus fees & expenses right off the top: a ballpark figure of a 2.7 million dollar pay day (not bad for not preparing or having cases ready for trial.....just sitting around in some backroom swinging a sweet deal for themselves)

Then the Garretson Resolution Group is calculated into the racket for their piece of the action: (they do the paper work, create the "sell the settlement" packets, and barter lean resolution for a nice slice of pie somewhere in the neighborhood of  $260,000 dollars

Then Uncle Sam steps in & takes their % cut for Medicare/Medicaid reimbursement; plus there are other potential private leans or outstanding debts that can be deducted...this amount will vary for each client/state/&situation.

Then at the very tail end of the settlement feast; the injured party receives their actual paltry offer; which averages in the neighborhood of 4 to 5 thousand dollars.

So as you can see: everyone has their hands in the settlement cookie jar, except the actual injured parties. The lawyers get rich and move on to their next drug or device litigation for another backroom golden deal. All the tag a longs like Garretson grab their share. 

And probably the greatest injustice of all is that AstraZeneca clears the slate; paying out virtually nothing to forever cover their criminal actions and the damage Seroquel has directly caused (& will continue to cause) to many thousands of innocent citizens; while AZ has made & will continue making untold billions of dollars in pure profit.














Friday, March 9, 2012

FDA acts with reckless abandon denying AstraZeneca's Citizen Petition regarding generic Seroquel labeling

FDA responds to AstraZeneca Citizen Petitions on quetiapine product labelling

Friday, 9 March 2012
AstraZeneca today announced that on 7 March 2012, the FDA denied Citizen Petitions requesting that the FDA withhold finally approving any generic quetiapine product with labelling that omits certain hyperglycaemia warning language that the FDA required AstraZeneca to include in the labelling for SEROQUEL® (quetiapine fumarate) and SEROQUEL XR® (quetiapine fumarate).

The U.S. FDA acts with reckless endangerment when it omits ANY drug side effect warnings from the label of the antipsychotic Seroquel (quetiapine). The antipsychotic is being prescribed for off-label use for insomnia, anxiety, for PTSD, to war veterans, to children--and the FDA which could act as a gatekeeper for drug safety---continues to promote the use of this dangerous product by actions like this. The fact that the drug made its way to the market place with a background of buried data and internal documents that show AstraZeneca's intent to market the drug anyway should be enough to pull this drug from sales. Instead it receives numerous and seemingly endless indications and now is on its way to generic version. The off-label prescribing will only increase with that version available! 
AstraZeneca's Citizen Petition appears to be one of serving the public, but make no mistake that was a move to keep this drug non-generic as long as possible for $$$ The major drug company with over 26,000 lawsuits for diabetes (which still is being ironed out, as the plaintiffs have not received settlements yet) suddenly wants to display all hyperglycemia related labeling on generics? 
Why didn't AstraZeneca display that on the product label from the beginning? The company buried Study 15, skewed data and KNEW the drug could cause weight gain and diabetes! NOW they want to be treated equally? If the generic drug doesn't have all the warning labels we were required to have then let's complain to the FDA? I smell $$$$$$$! 

This news on the heels of a commentary published in the Australian & New Zealand Journal of Psychiatry

Quetiapine-related harms are on the rise

  1. Cherie E Heilbronn1
  2. Belinda Lloyd1
  3. Paul McElwee1
  4. Alan Eade2
  5. Dan I Lubman1
  1. 1Turning Point Alcohol and Drug Centre, Eastern Health and Monash University, Victoria, Australia
  2. 2Ambulance Victoria, Victoria, Australia
  1. Belinda Lloyd, Turning Point Alcohol and Drug Centre, 54−62 Gertrude Street, Fitzroy, VIC 3065, Australia. Email: belindal@turningpoint.org.au
To the Editor
In the December 2010 issue, Hollingworth et al. (2010) detailed increased prescribing of atypical antipsychotic medications in Australia between 2002 and 2007. While olanzapine and risperidone remain the most commonly prescribed atypical antipsychotics, quetiapine prescribing is increasing, with PBS prescriptions rising by 27% between 2008/09 (431,096) and 2009/10 (545,410) (Department of Health and Ageing, 2010). Reasons for the growing use (including off-label prescribing) relate to its sedative properties and favourable extrapyramidal and metabolic profile, as well as emerging evidence of positive outcomes at low doses for a range of mental disorders (Hollingworth et al., 2010).
While the toxicity profile of atypical antipsychotics is considered preferable to typical agents, particularly regarding overdose risk, recent literature has called the relative safety of quetiapine into question. In one study, quetiapine-related overdoses were more likely to result in hypotension, respiratory depression, coma, or death than all the other antipsychotics combined (Ngo et al., 2008). This is particularly concerning given the growing number of case reports citing quetiapine as a potential substance of misuse, a phenomenon unseen with other atypical antipsychotic preparations (Sansone and Sansone, 2010).
A recent study (Lloyd and McElwee, 2011) identified a non-significant increase in antipsychotic-related ambulance attendances over 2000−2009 in metropolitan Melbourne. While demographic characteristics remained relatively consistent over the period, there was a significant increase in antipsychotic-related attendances where other drugs (both licit and illicit) were also implicated in presentations. However, differential harms across different antipsychotic preparations have not been adequately explored at a community level.
To further our understanding of this emerging issue, we analysed ambulance attendance data from metropolitan Melbourne across different antipsychotic preparations to provide a preliminary quantification of quetiapine-related harms. Data were derived from the Ambo Project database (Lloyd and McElwee, 2011), utilizing data from patient care records completed by paramedics, with additional coding undertaken to identify involvement of alcohol or other drugs in ambulance presentations. While there was a small increase in antipsychotic-related ambulance attendances between 2000/01 and 2009/10 (from 783 to 1074 attendances), quetiapine-related attendances increased substantially over the same period (from 32 in 2000/01 to 598 in 2009/10). Similar increases were not found for other antipsychotic preparations.
Anecdotal reports from Victorian alcohol and drug agencies participating in the Earlier Identification of Drug Harms Project (unpublished data) indicate that quetiapine demand, use, diversion, misuse, and harms are ongoing issues, particularly for clients with a history of illicit drug use. Over the course of this project involving bi-monthly data collection, quetiapine was the only antipsychotic consistently reported as being used in a problematic manner, regardless of source of supply.
Such an increase in acute quetiapine-related harm represents a growing public health issue. Further exploration is required to identify the nature and magnitude of quetiapine-related harms, population groups at increased risk of harm, prescribing trends, and strategies to ensure benefits of quetiapine are balanced against potential risks to patients, and costs to the community. In the meantime, it is important that clinicians are aware of growing misuse and diversion of quetiapine, and adopt prescribing practices that minimize the risk of harms.

Funding

This project is a collaborative project between Turning Point Alcohol and Drug Centre and Ambulance Victoria, and is funded by the Victorian Department of Health.

Acknowledgments

The authors would like to acknowledge and kindly thank Ambulance Victoria and its paramedics for their entry of data used in this study and Annie Haines for coding cases.